Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexa.P

Text File | 1997-01-27 | 6KB | 2 lines

Paget's disease,3,Pain,11,Pain Control Ladder,p19.8,PALA,4,Palliative care,4,Pancreas diagram,c13.8,Pancreas islet cell carcinoma,c08.2,Pancreatic cancer,13,Pancreatitis,c31.6,Pancreatectomy,c15.14,Pap smear,p02.5;p34.18,Papillary carcinoma,2,Papilloma bladder,c04.3;c04.17,Papillomatosis,c06.5,Paranasal sinus tumor,c14a.1;c14a.7;c14b.8,Parathyroid cancer,12,Parathyroid gland diagram,c42.6,Paregoric,p17.31;p18.20,Parenteral nutrition (TPN),p18.13,Parnate,c08.13,Passive immunotherapy,p08.6,Pathologist,p03.3,Patient controlled analgesia,p05.17,Patients Active,p30.2;p30.10,Patients Passive,p30.2,The Pediatric Oncology Group,c10a.12;c10a.15;c10b.1;c10b.8,Pediatrician,p03.3,Pelvic exenterahon,c09.24,Penectomy,c33.9,Penile cancer,10,Penis,c33.1,Pentamadine,c16.16,Peptamen,p18.12,Percocet,p19.8;p19.13,Percodan,0,Percutaneous gastrostomy (PEG),p18.12,Periactin,c08.8,Peridex,p17.17,Peridural anesthesia,p05.15,Peritoneum,c07.3;c07.14,Peutz-Jeghers syndrome,c38.4,Pharmacist,p03.6,Phenacetin,c04.4,Phenobarbital,c05.26,Phenoxybenzamine,c15.15,Pheochromocytoma,c01.1;c01.4;c01.6;c01.7;c01.8;c01.10;c01.14;c01.17,Pheoxybenzamine,c01.15,Philadelphia chromosome,p36.8,Phosphasoda,p17.24,Phosphorus radioactive,p06.10,Photocoagulahon therapy,c10c.4,Photodynamic therapy,p09.4;c37.19,Physical examination,2,Physical therapist,p03.5,Physical therapy,p24.5,Physician Data Query (PDQ) system,10,Pineal tumor child,c10b.2;c10b.7;c10b.18,Pinealblastoma,c05.10,Pituitary adenoma,c05.19,Pituitary cancer,8,Pituitary gland,c34.1,Plasma cell leukemia,c28.2,Plasmacytoma,c28.2;c28.3,Platinum,3,PNET (Primitive neuroectodermal tumor),c10a.2;c10b.6;c10b.7;c10b.10;c10d.1;c10d.10,Pneumonia,p12.12;p20.5,Podophyllin,c33.12,Polymerase chain reaction,c07.9,Polymorphonuclear leukocyte (PMN),p08.4,Ports,p05.7;p07.10,Positron emission tomography (PET scan),p33.10,Power of Attorney,p32.4;p32.5;p32.6,Pre-cancerous conditions,p05.3,Pre-deposit donation,p14.10,Precision Low Residue,p17.28,Preclinical drug testing,p35.3,Prednisone,7,Preferred Provider Organization (PPO),p32a.6,Preleukemia,c18.12,Preserved foods,p34.7,Prevention,8,Procarbazine,5,Prochlorperazine,chr.p17.14.,Procrit,c22.9,Progesterone,p07.6,Progression after chemotherapy,p07.5,Prolactin-producing tumor,c34.1;c34.6,Prolymphocytic leukemia,c18.28,Promyelocytic leukemia,p35.15,Propoxyphene,p19.8,Proscar,p34.24,Prostate cancer,16,Prostate Cancer Prevention Study,p34.24,Prostate Lung Colorectal and Ovarian Trial (PLCO),p34.24,Prostate specific antigen (PSA),p34.18,Prostatectomy,c35.12;c35.21;c35.32,Prostatic intraepithelial neoplasia (PIN),c35.2,Prosthesis esophageal,p09.9,Proto-oncogenes,p36.3,Provera,c16.22,Psychedelic drugs,p23.8,Psychologist,p03.5,Psychoneuroimmunology (PNI),p30.2;p30.11,Psychosocial care,p27.7,Psychotherapist,p03.5,Psyllium,p17.24,Pulmonary embolism post-operative,p05.20,Pumps,p05.10;p07.10;p07.12;p19.13,Pure endometrial stromal sarcomas,c45.2;c45.3;c45.13;c45.14,Pure red cell aplasia,c41.2;c41.5,Pyridium,p06.18,
bone,c02.2;c36.4,breast,c06.3;c06.10,vulva,c47.2;c47.18,after hormone therapy,c06.46,after hyperthermia,p10.5,after surgery,p05.17,causes,p19.3,controlling,p19.7;p25.4;p26.12;p27.5,during intercourse,p23.3;p23.11,fear of,p19.1,from multiple myeloma,c28.17,sign of infection,p20.5,types,p19.3,when urinating,p06.18;p20.5,for colorectal cancer,c11b.9;c11b.13;c11b.20;c11c.8;c11c.10;c11c.14,for pancreatic cancer,c31.11;c31.19,for stomach cancer,c39.16,investigational drug,p35.10,defined,p27.1,goals,p27.5,range of services,p27.2,roles,p27.4,causes,c31.2,diagnosis,c31.6,investigational drugs,p35.9,questions to ask,c31.20,recurrence,c31.19,risk factors,c31.3,screening,c31.4,spread,c31.2,staging,c31.9,symptoms,c31.5,treatment,c31.10,types,c31.1,unknown primary site,c07.3;c07.7,endometrium,c44.2,thyroid,c42.2;c42.3;c42.17,causes,c32.2,diagnosis,c32.6,follow-up,c32.12,questions to ask,c32.14,recurrence,c32.13,risk factors,c32.3,screening,c32.4,spread,c32.2,staging,c32.8,symptoms,c32.5,treatment,c32.9,types,c32.2,causes,c33.2,diagnosis,c33.6,questions to ask,c33.13,risk factors,c33.3,screening-c334, ,and sexuality 169 ,0,spread,c33.1,symptoms,c33.5,treatment,c33.7,types,c33.1,breast,c06.9,importance,p02.4;p20.6;p34.17,access,p37.14,clinical trials,p37.9,currency,p37.5,directory,p37.13,format,p37.4,information available,p37.3,organization,p37.2,participating organizations,chr.p37.15,participating societies,chr.p37.12,protocol file,p37.7,causes,c34.2,diagnosis,c34.4,follow-up,c34.8,questions to ask,c34.9,spread,c34.2,symptoms,c34.3,treatment,c34.5,types,c34.1,for lung cancer,c20.10,for osteogenic sarcoma,c10d.8,for stomach cancer,c39.16,for breast cancer,c06.37,for Hodgkin's disease,c23.15;c23.16;c23.17,for leukemia,c18.19,for lymphoma,c22.8;c24.16;c24.18;c24.19;c24.20;c24.21,for multiple myeloma,c28.12;c28.14;c28.20,for thymus cancer,c41.9;c41.10,to restore appetite,p17.20,advances in,c33.9,advocacy for,p34.25,community initiatives,p34.23,defined,p34.2,guidelines,p34.11,prostate cancer,p34.24,skin cancer,c37.7,surgical,p05.3,for brain cancer,c05.17,for gastrointestinal tract cancer,c08.13,for Hodgkin's disease,c23.16;c23.17,for lymphoma,c24.16;c24.20,side effects,chr.p17.13,causes,c35.3,diagnosis,c35.9,diagrams,c35.3;c35.20;c35.23;c35.24;c35.25;c35.26;c35.28,follow-up,c35.34,prevention,p34.24,questions to ask,c35.37,recurrent,c35.36,risk factors,c35.4,screening,c35.6,and sexuality,p23.8,spread,c35.2,staging,c35.11,symptoms,c35.8,treatment,p34.23;c35.12,types,c35.2,unknown primary site,c07.1;c07.6;p07.15,